Drug Topics
MARCH 29, 2024
After semaglutide and tirzepatide were approved, and ozempic use continues to rise, Medicare spending is also increasing because of a high demand for GLP-1 therapies.
STAT
MARCH 29, 2024
For babies who are breastfed, their first source of sustenance is filled with proteins, sugars, hormones, vitamins, and minerals — just the right amount of nutrients for an infant. That milk could also lower the risk of asthma , diabetes, and allergies. And it could make low-birth-weight, preterm babies up to 10 times less likely to develop necrotizing enterocolitis , a common intestinal disorder.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
MARCH 29, 2024
Researchers found various reasons for why individuals chose a specific pharmacy and how they purchase OTC medication.
Fierce Healthcare
MARCH 29, 2024
With AI being all the buzz in healthcare today, many questions about the technology still remain. Do clinicians understand and trust AI tools? Are algorithms accurate and free from bias? | At the 2024 SXSW conference, a panel on the future of AI in healthcare moderated by AMA President Jesse Ehrenfeld, M.D., discussed what's still needed for safer, more integrated and more impactful systems.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Drug Topics
MARCH 29, 2024
Thanks to the Inflation Reduction Act, Medicare Part B coinsurance rates will lower if drug prices rise faster than the rate of inflation.
STAT
MARCH 29, 2024
Diabetes drugs are too expensive in the U.S., and insulin is infamously six to 13 times more expensive here than in comparable high-income countries. And blockbuster GLP-1 drugs, too, could be a lot less expensive, according to an investigation published this week in JAMA Network Open, with a simple change: robust generic competition. The study, led by Melissa Barber, a Yale postdoctoral fellow, and conducted in collaboration with Doctors Without Borders, a nonprofit medical organization working
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Fierce Pharma
MARCH 29, 2024
Bristol Myers Squibb’s Zeposia (ozanimod) has attracted attention as a treatment for an unusual duo of diseases—multiple sclerosis (MS) and ulcerative colitis (UC). | Bristol Myers Squibb’s Zeposia has attracted attention as a treatment for an odd pair of unrelated diseases—multiple sclerosis (MS) and ulcerative colitis (UC). But the approval roll for the sphingosine 1-phosphate (S1P) receptor modulator may be over.
Pharmacy Times
MARCH 29, 2024
Pediatric patients with the variant were approximately 1.44 times more likely develop ALL compared with children who do not have the variant.
Fierce Pharma
MARCH 29, 2024
Bristol Myers Squibb looks on track to overtake Amgen as the KRAS leader in lung cancer after following up its rival’s FDA setback with a positive confirmatory trial readout. | Bristol Myers Squibb looks on track to overtake Amgen as the KRAS leader in lung cancer after following up its rival’s FDA setback with a positive confirmatory trial readout.
Fierce Healthcare
MARCH 29, 2024
As public health officials nationwide sound the alarm on a “tripledemic”—the emergence of the respiratory syncytial virus (RSV), the influenza virus and the COVID-19 virus simultaneously—pregnant w | Given that Medicaid and CHIP cover a significant portion of all pregnancies in America—especially for historically disadvantaged groups—policy actions could play a key role in supporting vaccine access and health equity.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmaceutical Commerce
MARCH 29, 2024
In this Pharmaceutical Commerce video interview, Barry Heavey, Life Sciences Supply Chain Lead, Accenture, discusses the specific factors contributing to rising manufacturing costs.
pharmaphorum
MARCH 29, 2024
Report claims US intelligence services advised the authors of the BIOSECURE Act that WuXi AppTec shared confidential data on US clients with the Chinese government
Fierce Pharma
MARCH 29, 2024
This week on “The Top Line,” we explore peripheral arterial disease, a serious health issue that is often overlooked and undermanaged. | This week on “The Top Line,” join Editor-in-Chief of Fierce Life Sciences and Healthcare Ayla Ellison as she sits down with Kumar Madassery, M.D., Director of Peripheral Vascular Intervention & CLI Program at Rush University Medical Center, to explore peripheral arterial disease—a serious health issue that is often overlooked and undermanaged.
Pharmacy Times
MARCH 29, 2024
The mutations, C594Y and P735R, were found in the GNE gene and may influence sialylation, a process that is crucial for brain development.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Fierce Pharma
MARCH 29, 2024
Once again, a medicine in the popular GLP-1 class of diabetes and weight loss therapies is facing supply hurdles. | While the drug is not listed on the FDA's shortage list, some pharmacies are facing supply issues. Amazon Pharmacy, for instance, notes that several dosage strengths are "unavailable.
Pharmacy Times
MARCH 29, 2024
The ODD comes after AP303 presented meaningful improvements in renal survival in an ADPKD and the completion of the first study that evaluated healthy human participants.
pharmaphorum
MARCH 29, 2024
Bristol-Myers Squibb's Zeposia has failed to outperform placebo in its first phase 3 test in Crohn's disease
STAT
MARCH 29, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello, everyone. Damian here with a look at key Supreme Court decision, the latest biotech IPO, and intrigue over Chinese outsourcing.
Pharmacy Times
MARCH 29, 2024
An overview of the use of direct oral anticoagulants as an alternative to warfarin in the treatment of left ventricular thrombus.
STAT
MARCH 29, 2024
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is still being formulated, but we do hope to promenade with the official mascots, catch up on our reading, and maybe stare at the telly now and then. Of course, we are also planning another listening party, where the rotation will include this , this , this and this.
Pharmacy Times
MARCH 29, 2024
The effects were strongest during the spring season and in the third trimester of pregnancy.
Fierce Pharma
MARCH 29, 2024
A little more than a year after Hikma Pharmaceuticals accused Amarin of “deliberately and meticulously” hamstringing supplies of the main ingredient in its only marketed drug, Vascepa, to thwart po | A little more than a year after Hikma Pharmaceuticals accused Amarin of “deliberately and meticulously” hamstringing supplies of the main ingredient in its only marketed drug, Vascepa, to thwart potential generic competition, Teva Pharmaceuticals has levied a similar challenge.
STAT
MARCH 29, 2024
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which we highlight a different person each week.
Pharmacy Times
MARCH 29, 2024
Christin Hackel discusses the current state of OTC contraception options, the differences between OTC and prescription methods, and how pharmacists can promote education and awareness.
PharmaVoice
MARCH 29, 2024
Rivus’ controlled metabolic accelerators are an emerging new potential competitor to popular weight loss and diabetes drugs from Novo Nordisk and Eli Lilly.
Compounding Pharmacy of America
MARCH 29, 2024
An exploration of how proper diet, exercise, and a regiment of supplements combined with GLP-1 therapies can prevent and treat type 2 diabetes. The post The Role of GLP-1 Therapies in Type 2 Diabetes Prevention and Treatment appeared first on The Compounding Pharmacy of America.
The FDA Law Blog
MARCH 29, 2024
By John W.M. Claud & Kalie E. Richardson — While Covid is in the rear view for most of us, FDA has had a tough time shaking off the effects of the pandemic on its inspection output. Inspections went down—way down—during the pandemic. In March 2020 , FDA temporarily postponed all foreign and domestic and routine surveillance facility inspections.
Pharmaceutical Commerce
MARCH 29, 2024
The latest news for pharma industry insiders.
Fierce Healthcare
MARCH 29, 2024
Virtual mental health company Brightside Health picked up $33 million in fresh funding to help propel its expansion into Medicare and Medicaid populations. | Virtual mental health company Brightside Health picked up $33 million in fresh funding to help propel its expansion into Medicare and Medicaid populations.
Pharmaceutical Technology
MARCH 29, 2024
Discover how Arvinas Inc's newly granted patent for compounds treating prostate cancer could revolutionize healthcare. Learn more about the potential for new drugs and therapies.
Fierce Healthcare
MARCH 29, 2024
A new year brings a new approach to tracking health tech and digital health investments. | A roundup of health tech and digital health financing rounds in March. Check out who picked up new investments.
Pharmaceutical Technology
MARCH 29, 2024
Discover the groundbreaking patent by Yield10 Bioscience Inc for a genetically engineered oilseed plant expressing a plant protein, revolutionizing biotechnology in agriculture.
pharmaphorum
MARCH 29, 2024
Explore the key aspects of clinical trial supply management, including insights on Clinigen and its role in supporting clinical research trials. Learn how this backbone of breakthroughs can drive success in clinical trials.
Pharmaceutical Commerce
MARCH 29, 2024
In this Pharmaceutical Commerce video interview, Joerg Tritschler, a partner in Simon-Kucher’s life sciences division, discusses the hottest therapeutic settings for dealmaking activity at the moment—and one platform approach in particular poised to be at the center of future M&A and licensing pursuits.
Expert insights. Personalized for you.
211 
Let's personalize your content